March 2020 - In-vivo proof of concept for 4D Lifetest™ approved

4D Lifetec has reached the next important milestone in the development and marketing of its liquid biopsy assay 4D Lifetest™. With the reliable detection of prostate and lung cancer within our clinical studies with cancer patients, a standard protocol has been established in recent months that establishes the biomarker DRC (DNA Repair Capacity) as an effective cancer biomarker and allows our test to effectively identify cancer.

In order to ensure the evaluation of these results by 4D Lifetec, an independent technology assessment was conducted. An external biomarker expert with many years of experience in biomarker test development at large diagnostic companies, Dr. Frank Städtler, was contracted. Based on his detailed assessment (see attachment), the in-vivo Proof of Concept for the 4D Lifetest™ has now been approved.

 Read here the Independent Technology Assessment